Do GLP-1 Medications Cause Blood Clots? Understanding the Risks and Mechanisms

Last reviewed: June 16, 2026

Last updated: June 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 medications like semaglutide and tirzepatide help millions manage weight and metabolic health, but questions about safety—particularly regarding blood clots—deserve clear, evidence-based answers. Research conducted across major cardiovascular outcome trials has not identified GLP-1 receptor agonists as independent risk factors for venous or arterial thrombosis in standard populations.

What Does Current Clinical Evidence Show About GLP-1 and Blood Clots?

Large-scale cardiovascular safety trials, including the LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide, did not report increased blood clot incidence as a primary safety concern. These studies tracked thousands of participants over several years and focused on heart attacks, strokes, and cardiovascular mortality—conditions where clotting plays a central role. The absence of a signal for thrombotic events in these rigorous datasets provides substantial reassurance about GLP-1 safety in this domain.

One important distinction: some early clinical observations noted rare cases of thrombotic events in specific patient subgroups, particularly those with existing clotting disorders or recent surgeries. However, these observations remain anecdotal and have not translated into warnings in prescribing information for GLP-1 medications. PlexusDx compounded semaglutide comes from licensed 503A compounding pharmacies that follow the same safety standards as branded medications, ensuring quality and consistency.

How GLP-1 Medications Affect Blood Vessel Function and Clotting

GLP-1 receptor agonists work primarily in the pancreas and gastrointestinal tract to regulate blood sugar and appetite, but they also activate GLP-1 receptors on blood vessel walls. This activation may actually have a protective effect: GLP-1 signaling improves endothelial (inner lining) function and reduces inflammation—both factors that normally decrease clot formation rather than increase it. Weight loss itself, a primary outcome of GLP-1 therapy, is associated with improved blood flow and reduced clotting tendency.

The mechanisms that might theoretically increase clot risk—such as blood vessel injury, stasis (slow blood flow), or increased blood viscosity—are not commonly observed with GLP-1 use. In fact, improvements in blood pressure, cholesterol levels, and platelet function documented in many GLP-1 trials suggest a net reduction in thrombotic risk, especially when weight loss is achieved and sustained.

Who Should Be Most Cautious About GLP-1 and Clotting Risks?

Patients with a personal or strong family history of blood clots, inherited thrombophilias (genetic clotting disorders), or active malignancy warrant closer physician oversight before starting GLP-1 therapy. Similarly, those scheduled for major surgery should discuss timing of GLP-1 injections or oral doses with their surgical team, as any medication affecting blood vessel function deserves consideration in perioperative planning. PlexusDx recommends reviewing your complete medical history with the supervising physician before initiating treatment.

Dehydration can increase blood viscosity and clot risk independently of medication choice. GLP-1 users should maintain adequate hydration, especially during the dose-escalation phase when gastrointestinal side effects like nausea may reduce fluid intake. This simple preventive step addresses a modifiable risk factor without requiring dose adjustment or discontinuation of semaglutide or other GLP-1 compounds.

Personalized Risk Assessment With Precision Peptide Genetic Testing

PlexusDx offers the Precision Peptide Genetic Test, which examines genetic variants in pathways relevant to GLP-1 metabolism and response, including analysis of 49 peptides across 14 distinct metabolic pathways. While the test is not a pharmacogenomic thrombosis predictor, it does identify genetic predispositions in other peptide-signaling variants that influence how your body processes and responds to semaglutide and tirzepatide. Understanding these individual patterns helps PlexusDx physicians tailor dosing and compound selection for optimal safety and efficacy.

The Precision Peptide Genetic Test costs $298. This personalized approach complements standard clinical assessment and allows your PlexusDx provider to flag any genetic risk factors that might warrant additional monitoring or alternative therapy. Combined with baseline labs and health history review, genetic insights help ensure you receive the safest, most effective GLP-1 protocol.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does semaglutide increase the risk of blood clots?

No. Major clinical trials have not identified semaglutide as an independent cause of blood clots. Patients with existing clotting disorders or those undergoing surgery should inform their physician, but standard-risk individuals do not face elevated thrombotic risk from semaglutide therapy. PlexusDx semaglutide (at $189/mo month-to-month, or from $149/mo on the 6-month plan) is compounded by licensed 503A pharmacies meeting FDA standards.

What clinical trials tested GLP-1 safety for blood clots?

The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) enrolled thousands of patients and measured cardiovascular outcomes including thrombotic events. Neither study reported increased clot risk as a safety signal. These trials remain the gold standard for assessing GLP-1 thrombotic safety.

Can I afford GLP-1 treatment without insurance?

Yes. PlexusDx serves all 50 states with no insurance requirement and no membership fee. Compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), and both HSA and FSA accounts are eligible. Your dose may need to go up. Your price won't.

What should I do if I have a history of blood clots?

Inform your PlexusDx provider immediately during your medical history review. Patients with prior thrombosis, thrombophilia, or cancer require individualized risk assessment and may benefit from additional monitoring or alternative therapy. Your safety is the priority.

How does the Precision Peptide Genetic Test help assess clot risk?

The test ($298) analyzes 49 peptides and 150+ genetic insights including GLP1R variants and metabolic pathways relevant to your response to semaglutide. While not a clotting-disorder predictor, it identifies individual peptide-signaling patterns that help your PlexusDx physician optimize your protocol for safety and efficacy.

Related Reading

• Glp 1 For High Blood Pressure
• Glp 1 Medications
• Role Of Glp 1 In Blood Sugar Control And Diabetes Treatment
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.